Q2 revenue up 90% YoY, but supply constraints now cap the upside; company raises guidance and capital to invest through the bottleneck.
AMBQ · Earnings Call · 2026-08-11
Shortage of Supply, Not Demand, Now Caps Ambiq's Outlook
Ambiq Micro's second quarter was a study in contradiction: net sales grew 89.7% year-over-year to $33.9 million, marking a fifth consecutive sequential gain, yet the real narrative is what the company couldn't ship. CEO Fumihide Esaka was unambiguous about the demand environment: “Our customers' demand is skyrocketing… a lot of additional demand is coming in week after week.” — Fumihide Esaka, CEO · 2026-08-11 The bottleneck is not orders—it's wafers, packaging, substrates, and test capacity. The company is working closely with supply chain partners to secure allocations, but as Esaka noted, even with those actions the second-half outlook is constrained.
A couple of customers introduced a brand-new product back in May. Their preorder quantity was 3 to 5x of what even they expected. So to meet that demand, they wanted a product in June that's physically impossible.
That supply ceiling is the single most important change versus prior quarters—demand is no longer the variable; capacity is.
This is not a temporary blip. Esaka expects the constraint to persist into 2027, and Ambiq is betting big on that view. The company raised approximately $168 million in net proceeds from a June follow-on offering, which followed an earlier raise this year, totaling about $243 million. Management is deploying that cash to fund working capital, product development, and supply-chain flexibility. The full-year revenue guide was lifted to approximately $135 million—roughly double last year—even with supply limits. The Edge AI wave is real, and Ambiq is riding it, but the margin for error has shifted from design wins to execution on manufacturing.
Gross Margin Expansion and Financial Discipline
Amid the chaos, Ambiq delivered a pleasant surprise on profitability. Non-GAAP gross margin came in at 47.2%, up 450 basis points year-over-year, and the company now expects modest margin improvement for the full year—a reversal from its earlier guidance of flat margins. CFO Jeffrey Winzeler attributed the gain to two factors: pricing power and manufacturing efficiency. “We continue to win business and price our products to extract the maximum value… We've also made a lot of progress on the actual manufacturing costs associated with our products, primarily through yield improvements and test time improvements.” — Jeffrey Winzeler, CFO · 2026-08-11 This is a meaningful validation of Ambiq's Power efficiency value proposition—customers are paying for the low-power advantage, and the company is getting better at delivering it at scale. Even with rising industry cost pressures, the margin trajectory is encouraging.
The OpEx picture is more nuanced. Non-GAAP R&D rose 55.5% year-over-year to $11.2 million, and total non-GAAP operating expenses for Q3 are guided to $24–25 million, reflecting a step-up in investments around Atomiq 110 and Apollo 340 development, including $2 million of IP purchases. Winzeler reiterated the full-year OpEx envelope of approximately $85 million, with $7–10 million dedicated to IP. This is a deliberate growth-over-profitability tradeoff. As he said in Q&A: “We're very much focused on a growth model right now… we've raised quite a bit of money… specifically to give us the cash resources to both grow our existing pipeline of business as well as develop new business opportunities.” — Jeffrey Winzeler, CFO · 2026-08-11 The balance sheet is clean—no debt and $366.8 million in cash—so the loss is a funding choice, not a distress signal.
Product Roadmap and Diversification
Ambiq's growth is not just a wearable story. While wearables remain the core, the company is broadening into medical, industrial, and smart-home applications. The funnel of new designs outside wearables still sits at roughly 25% of total, and revenue from those markets is expected to more than double in 2026. Winzeler highlighted a diverse set of use cases—from Holter monitors to seabed sensing—and noted that module partners extend the company's reach. Apollo 340 and the newly introduced Apollo 330 Plus and Apollo 510 Light families are designed to serve that breadth, and early customer engagement is strong. CTO Scott Hanson provided an update on the Atomiq line: “The early development platform is in customer hands in the form of an FPGA, and we're getting a lot of useful feedback… it's interest that spans a couple of different markets.” — Scott Hanson, Founder and CTO · 2026-08-11 Atomiq 110 and Apollo 340 remain on track for customer sampling in early 2027, with meaningful revenue expected in 2028.
That product cadence is critical because it signals Ambiq is not just a one-hit wonder. The company is building a portfolio that can compound its Power efficiency advantage across more endpoints. The Total Revenue trajectory—from $16M in early 2025 to $25M in Q1 2026 and now $33.9M in Q2—shows the acceleration is real. But the real test will be whether management can execute on the supply side and convert the deferred demand into 2027 revenue. Prior calls already hinted at this tension. In May, Esaka acknowledged the same issue when asked about expedites: “Sometimes we get such a short lead time demand increase… some of the order we just can't meet because of the too short of lead time.” — Fumihide Esaka, Chief Executive Officer (CEO) · 2026-05-12 And in March, Winzeler flagged that IP spending would be project-based and tied to tape-outs in the second half: “The last place that we will spend a significant amount of money is in our IP acquisition… that is very project-based.” — Jeffrey Winzeler, CFO · 2026-03-05 Today, those themes have crystallized into the defining challenge of the year.
The stock's reaction tells the story: after a massive run-up to $90.48 in mid-June, AMBQ has pulled back roughly 35%, reflecting the supply overhang. But the fundamental picture is improving, not deteriorating. Ambiq is a small-cap semiconductor with a differentiated technology, a booming end-market, and now a war chest to invest. The question is not whether demand exists—it does—but whether the company can scale fast enough to satisfy it. For now, the answer is constrained, but the trajectory is clear.
Ambiq's Q2 was a proving ground for its thesis: Edge AI is reshaping devices, and power efficiency is the gatekeeper. The company is doing exactly what it should—raising capital, expanding capacity, and advancing its roadmap. The supply ceiling may temper near-term numbers, but it is also a testament to demand that most companies would envy. Watch for updates on capacity additions and the pace of Atomiq sampling; those will determine whether Ambiq can turn this bottleneck into a durable growth story.